Resveratrol inhibits heregulin-β1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells

Journal of Nutritional Biochemistry

Volumn 19, Issue 5, 2008, Pages 287-294

  Tang, Feng Yao ^a   Chiang, En Pei Isabel ^a   Sun, Ya Chi ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Heregulin 1; Human breast cancer cells; Matrix metalloproteinase; Mitogen activated protein kinase; Resveratrol; Tissue inhibitor metalloproteinase protein

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE B; HEREGULIN BETA 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEU DIFFERENTIATION FACTOR; RESVERATROL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEUREGULIN-1; PHOSPHORYLATION; RECEPTOR, ERBB-2; STILBENES; TISSUE INHIBITOR OF METALLOPROTEINASES;

VITACEAE;

EID: 41849090120     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2007.03.003     Document Type: Article

References (32)

1. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
2. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 (2001) 463-516
3. Westermarck J., and Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13 (1999) 781-792
4. Jones J.L., Glynn P., and Walker R.A. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189 (1999) 161-168
5. Scorilas A., Karameris A., Arnogiannaki N., Ardavanis A., Bassilopoulos P., Trangas T., et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 84 (2001) 1488-1496
6. Pellikainen J.M., Ropponen K.M., Kataja V.V., Kellokoski J.K., Eskelinen M.J., and Kosma V.M. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10 (2004) 7621-7628
7. Tan M., Yao J., and Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57 (1997) 1199-1205
8. Tsai M.S., Shamon-Taylor L.A., Mehmi I., Tang C.K., and Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 22 (2003) 761-768
9. Braun S., Schlimok G., Heumos I., Schaller G., Riethdorf L., Riethmuller G., et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61 (2001) 1890-1895
10. Hellstrom I., Goodman G., Pullman J., Yang Y., and Hellstrom K.E. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 61 (2001) 2420-2423
11. Goebel S.U., Iwamoto M., Raffeld M., Gibril F., Hou W., Serrano J., et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 62 (2002) 3702-3710
12. Wen Y., Hu M.C., Makino K., Spohn B., Bartholomeusz G., Yan D.H., et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60 (2000) 6841-6845
13. Tanner M., Hollmen M., Junttila T.T., Kapanen A.I., Tommola S., Soini Y., et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16 (2005) 273-278
14. Lupu R., Cardillo M., Cho C., Harris L., Hijazi M., Perez C., et al. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 38 (1996) 57-66
15. Bodey B., Bodey Jr. B., Groger A.M., Luck J.V., Siegel S.E., Taylor C.R., et al. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 17 (1997) 1319-1330
16. Charoenrat P., Rhys-Evans P., Court W.J., Box G.M., and Eccles S.A. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands. Clin Exp Metastasis 17 (1999) 631-639
17. Xu F.J., Stack S., Boyer C., O'Briant K., Whitaker R., Mills G.B., et al. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 3 (1997) 1629-1634
18. Jinga D.C., Blidaru A., Condrea I., Ardeleanu C., Dragomir C., Szegli G., et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 10 (2006) 499-510
19. Jung S.A., Yang S.K., Kim J.S., Shim K.N., Im S.A., Myung S.J., et al. The expression of matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs) and angiogenesis in relation to the depth of tumor invasion and lymph node metastasis in submucosally invasive colorectal carcinoma. Korean J Gastroenterol 45 (2005) 401-408
20. Murphy G., and Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 248 (1995) 496-510
21. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., and Marmer B.L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267 (1992) 4583-4591
22. Li F., Strange R., Friis R.R., Djonov V., Altermatt H.J., Saurer S., et al. Expression of stromelysin-1 and TIMP-1 in the involuting mammary gland and in early invasive tumors of the mouse. Int J Cancer 59 (1994) 560-568
23. Nakopoulou L., Giannopoulou I., Stefanaki K., Panayotopoulou E., Tsirmpa I., Alexandrou P., et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 197 (2002) 307-313
24. Sun C.Y., Hu Y., Guo T., Wang H.F., Zhang X.P., He W.J., et al. Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity. Acta Pharmacol Sin 27 (2006) 1447-1452
25. Woo J.H., Lim J.H., Kim Y.H., Suh S.I., Min D.S., Chang J.S., et al. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 23 (2004) 1845-1853
26. Sun C., Hu Y., Liu X., Wu T., Wang Y., He W., et al. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 165 (2006) 9-19
27. Ikenaka Y., Yoshiji H., Kuriyama S., Yoshii J., Noguchi R., Tsujinoue H., et al. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 105 (2003) 340-346
28. Basset P., Okada A., Chenard M.P., Kannan R., Stoll I., Anglard P., et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 15 (1997) 535-541
29. Johnsen M., Lund L.R., Romer J., Almholt K., and Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10 (1998) 667-671
30. Lin M.T., Yen M.L., Lin C.Y., and Kuo M.L. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 64 (2003) 1029-1036
31. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5 (2006) 493-506
32. Tang F.Y., Chiang I.E.P., and Shih C.J. Green tea catechin inhibits ephrin A1-mediated cell migration and angiogenesis of human umbilical vein endothelial cells. J Nutr Biochem 18 (2007) 391-399